Industry News
Pharmaceutical Industry News
The Biotechnology Innovation…
The Biotechnology Innovation Organization has started the nationwide “The Fight of Our Lives” campaign, creating a video and other materials to show the stories behind biotech breakthroughs and their effects on patients.
Help for Medicare Advantage Patients Who Lose Doctors Is Shelved, for Now
Nationwide, hospitals and other providers are leaving private Medicare Advantage plans, putting thousands of seniors at risk of higher costs and of losing trusted doctors.
Batch of Anti-Anxiety Drug Xanax Recalled, F.D.A. Says
The recall affects only a small number of pills, sold nationwide under the brand name Xanax XR.
The company highlights the…
The company highlights the features of its AI-powered Verily Me app in two 30-second spots that launched across national TV, audio and social channels.
Viatris and Teva Pharmaceutical…
Viatris and Teva Pharmaceutical Industries recently launched separate recalls related to dissolution problems for a common anxiety medication and concerns around an unapproved raw material in a high blood pressure patch, respectively.
The anti-amyloid drug class has…
The anti-amyloid drug class has yielded some FDA approvals and plenty of failed candidates. Now, researchers are looking at the overall track record of the group and painting an unpleasant picture about the efficacy of
Rather than relying on patient…
Rather than relying on patient groups to make an impassioned plea, Roche aims to put doubts to rest around the controversial Duchenne muscular dystrophy gene therapy Elevidys with the rigor of another clinical study.
Eli Lilly is wasting no time in…
Eli Lilly is wasting no time in pursuit of the next indication for its newly christened obesity pill Foundayo, presenting new data in diabetes Thursday that also serves to address the FDA’s desire for more
Omnicom Health has stamped its…
Omnicom Health has stamped its mark on the recently acquired FCB Health New York, rebranding the ad agency as Olixir New York in the aftermath of the mega-merger with Interpublic Group.
Analysis of Alzheimer’s Drugs Stirs Debate About Their Effectiveness
The review said a certain class of drugs had little clinical benefit, but many Alzheimer’s experts criticized the analysis, saying it unfairly lumped failed drugs with two recently approved treatments.
GLP-1 Experimentation Is Everywhere, and Science Can’t Keep Up
Millions of Americans are experimenting with the drugs. Science can’t keep up.
The FDA’s Pharmacy Compounding…
The FDA’s Pharmacy Compounding Advisory Committee will convene this summer to discuss seven peptides that are currently restricted from use in compounded medications.
With Daiichi Sankyo’s priorities…
With Daiichi Sankyo’s priorities increasingly tied to its innovative medicines—and its oncology portfolio in particular—the Tokyo-based drugmaker is following in the footsteps of several of its peers with a deal to split from its consumer
Innovative treatment options like…
Innovative treatment options like targeted therapy and advanced molecular diagnostic techniques are opening new doors for patients.
Before committing to research, AI…
Before committing to research, AI is helping pharma teams identify which concepts are most likely to resonate with their key customers
The company and its global…
The company and its global distrubution partner the Global Fund expanded its commitment to bring Yeztugo to 3 million people worldwide by 2028, but Doctors Without Borders (MSF) says supply is still "not nearly enough."
AI heavyweight Anthropic has…
AI heavyweight Anthropic has appointed Novartis CEO Vas Narasimhan to its board of directors as the link between the pharmaceutical industry and Silicon Valley deepens.
For Astellas’ chief…
For Astellas’ chief manufacturing officer, Rao Mantri, Ph.D., production is not just about a reliable supply of a pharmaceutical product. Manufacturing serves as a crucial bridge that helps link promising research to patients in the
Lucy Liu has joined Pfizer’s…
Lucy Liu has joined Pfizer’s mission to deliver a knockout blow against cancer, becoming the latest face of the Big Pharma’s campaign encouraging people to get screened.
Just two months after the FDA…
Just two months after the FDA accepted for review Teva’s long-acting version of a decades-old schizophrenia drug, the Israeli pharma is launching a community project to help people with the disorder and their carers.